Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Resistance

Background:

• Targeted therapies for EGFR-mutant lung adenocarcinoma show initial efficacy but are limited by acquired resistance.
• The mechanisms driving the transition from drug tolerance to resistance, particularly without pre-existing resistant clones, are not fully understood.

Purpose of the Study:

• To investigate the role of Aurora kinase A (AURKA) in mediating acquired resistance to EGFR inhibitors in lung adenocarcinoma.
• To explore the potential of targeting AURKA as a strategy to overcome resistance and enhance EGFR inhibitor efficacy.

Main Methods:

• Utilized EGFR-mutant lung adenocarcinoma cell lines and preclinical models.
• Investigated the activation of AURKA and its coactivator TPX2 in response to chronic EGFR inhibition.
• Assessed the impact of AURKA inhibition on drug response and apoptosis.
• Correlated AURKA activation with clinical resistance in patient samples.

Main Results:

• Acquired resistance to EGFR inhibitors in lung adenocarcinoma requires AURKA activity.
• Nongenetic resistance emerges via TPX2-mediated activation of AURKA, which suppresses apoptosis.
• Inhibition of AURKA enhances the efficacy and duration of EGFR inhibitor treatment in preclinical models.
• Treatment-induced AURKA activation is a common mechanism of resistance in vitro, in vivo, and in patients.

Conclusions:

• AURKA plays a critical role in the emergence of drug tolerance and acquired resistance to EGFR inhibitors.
• Targeting AURKA represents a promising synthetic lethal strategy to overcome resistance and improve outcomes for patients with EGFR-mutant lung adenocarcinoma.